Potential impact of immunobiotechnology on cancer therapy.
Genetic engineering techniques allow large scale production of substances generated during the immune response and these may have therapeutic value by modifying the biological response to cancer.
D001709:Biotechnology; D006801:Humans; D007109:Immunity; D007167:Immunotherapy / Q000639:trends*; D007372:Interferons / Q000627:therapeutic use; D007376:Interleukin-2 / Q000627:therapeutic use; D007694:Killer Cells, Natural / Q000276:immunology; D008233:Lymphotoxin-alpha / Q000627:therapeutic use; D009369:Neoplasms / Q000628:therapy*; D014409:Tumor Necrosis Factor-alpha / Q000627:therapeutic use
D007376:Interleukin-2; D008233:Lymphotoxin-alpha; D014409:Tumor Necrosis Factor-alpha; D007372:Interferons